KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) EBT (2016 - 2025)

Biogen has reported EBT over the past 17 years, most recently at -$56.0 million for Q4 2025.

  • Quarterly results put EBT at -$56.0 million for Q4 2025, down 119.21% from a year ago — trailing twelve months through Dec 2025 was $1.6 billion (down 18.34% YoY), and the annual figure for FY2025 was $1.6 billion, down 18.34%.
  • EBT for Q4 2025 was -$56.0 million at Biogen, down from $557.3 million in the prior quarter.
  • Over the last five years, EBT for BIIB hit a ceiling of $1.4 billion in Q3 2022 and a floor of -$141.2 million in Q3 2023.
  • Median EBT over the past 5 years was $457.9 million (2024), compared with a mean of $504.8 million.
  • Biggest five-year swings in EBT: soared 419.41% in 2024 and later tumbled 119.21% in 2025.
  • Biogen's EBT stood at $405.0 million in 2021, then surged by 49.09% to $603.8 million in 2022, then tumbled by 51.71% to $291.6 million in 2023, then decreased by 0.03% to $291.5 million in 2024, then tumbled by 119.21% to -$56.0 million in 2025.
  • The last three reported values for EBT were -$56.0 million (Q4 2025), $557.3 million (Q3 2025), and $744.0 million (Q2 2025) per Business Quant data.